Markets

Cancer diagnostics developer VolitionRx files for a $12 million NYSE MKT listing

An image of a pen and a calculator
Credit: Shutterstock photo

VolitionRx, which is developing blood-based diagnostic tests that detect cancer, filed on Friday with the SEC to raise up to $12 million and uplist on the NYSE MKT. The company is currently traded on the OTCQB Marketplace under the symbol VNRX, and has a market value of about $50 million.

The Singapore-based company, which was founded in 1998, plans to list on the NYSE MKT under the symbol VNRX. National Securities and Lake Street Capital Markets are the joint bookrunners on the deal. No pricing terms were disclosed.

The article Cancer diagnostics developer VolitionRx files for a $12 million NYSE MKT listing originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

VNRX

Other Topics

IPOs